Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Payables: 2016-2024

Historic Payables for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $37.8 million.

  • Rocket Pharmaceuticals' Payables fell 23.90% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.0 million, marking a year-over-year decrease of 5.90%. This contributed to the annual value of $37.8 million for FY2024, which is 17.39% down from last year.
  • As of FY2024, Rocket Pharmaceuticals' Payables stood at $37.8 million, which was down 17.39% from $45.8 million recorded in FY2023.
  • Rocket Pharmaceuticals' Payables' 5-year high stood at $45.8 million during FY2023, with a 5-year trough of $19.6 million in FY2021.
  • Its 3-year average for Payables is $40.1 million, with a median of $37.8 million in 2024.
  • In the last 5 years, Rocket Pharmaceuticals' Payables slumped by 35.36% in 2021 and then skyrocketed by 86.90% in 2022.
  • Rocket Pharmaceuticals' Payables (Yearly) stood at $30.3 million in 2020, then plummeted by 35.36% to $19.6 million in 2021, then spiked by 86.90% to $36.7 million in 2022, then grew by 24.90% to $45.8 million in 2023, then declined by 17.39% to $37.8 million in 2024.